Reviewing Allena Pharmaceuticals (ALNA) & ZIOPHARM Oncology (ZIOP)

Allena Pharmaceuticals (NASDAQ: ALNA) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends.

Profitability

This table compares Allena Pharmaceuticals and ZIOPHARM Oncology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Allena Pharmaceuticals N/A N/A N/A
ZIOPHARM Oncology -818.19% N/A -47.07%

Analyst Recommendations

This is a summary of current ratings and target prices for Allena Pharmaceuticals and ZIOPHARM Oncology, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allena Pharmaceuticals 0 0 4 0 3.00
ZIOPHARM Oncology 0 1 2 0 2.67

Allena Pharmaceuticals presently has a consensus target price of $24.67, suggesting a potential upside of 161.58%. ZIOPHARM Oncology has a consensus target price of $16.50, suggesting a potential upside of 221.01%. Given ZIOPHARM Oncology’s higher probable upside, analysts clearly believe ZIOPHARM Oncology is more favorable than Allena Pharmaceuticals.

Institutional and Insider Ownership

40.2% of ZIOPHARM Oncology shares are owned by institutional investors. 10.4% of ZIOPHARM Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Allena Pharmaceuticals and ZIOPHARM Oncology’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Allena Pharmaceuticals N/A N/A -$24.50 million ($1.03) -9.16
ZIOPHARM Oncology $6.86 million 106.37 -$165.29 million ($0.52) -9.88

Allena Pharmaceuticals has higher earnings, but lower revenue than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than Allena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Allena Pharmaceuticals beats ZIOPHARM Oncology on 6 of the 11 factors compared between the two stocks.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply